Crespi Erica J, Steckler Teresa L, Mohankumar Puliyur S, Padmanabhan Vasantha
Reproductive Sciences Program, 300 N. Ingalls Bldg, Rm 1109 SW, Ann Arbor, MI 48109-0404, USA.
J Physiol. 2006 Apr 1;572(Pt 1):119-30. doi: 10.1113/jphysiol.2005.103929. Epub 2006 Feb 16.
Experimental elevation of maternal testosterone (T) from 30 to 90 days of gestation leads to intrauterine growth retardation (IUGR) and increased prepubertal growth rate in female lambs. This study tested the hypothesis that prenatal T treatment during mid-gestation alters the trajectory of the fetal insulin-like growth factor (IGF)-insulin-like growth factor binding protein (IGFBP) system to promote IUGR and subsequent postnatal catch-up growth in female lambs. Plasma IGF-I and IGFBPs were measured by radioimmunoassay and Western ligand blot, respectively, on 65, 90 and 140 days (d) of gestation, at birth, approximately 5 months (prepubertal, the catch-up growth period), and approximately 9.5 months (postpubertal). Northern blot analysis was used to measure hepatic mRNA content of IGF system components during fetal stages. At fetal 65 d, plasma protein and hepatic mRNA content of IGFBP-1, an inhibitor of IGF bioactivity, was elevated in prenatal T-treated fetuses although body weight did not differ. There was a transient increase in plasma IGF-I and IGFBP-3 concentrations at fetal 90 d in prenatal T-treated fetuses. Hepatic IGF-I mRNA and plasma IGFBP-3 content were reduced by 140 d when body weight was reduced in prenatal T-treated fetuses. Plasma IGFBP-2 content was significantly reduced in prenatal T-treated newborns, but by 4 months these females had significantly higher circulating IGF-I and IGFBP-3 concentrations and faster growth rates than control females. After puberty, plasma IGF-I remained elevated in prenatal T-treated females. These findings provide evidence that prenatal T excess programmes the developmental trajectory of the IGF/IGFBP system in female sheep to reduce IGF bioavailability during IUGR and increase IGF bioavailability during prepubertal catch-up growth.
在妊娠30至90天期间实验性提高母羊睾酮(T)水平会导致雌性羔羊宫内生长迟缓(IUGR),并提高其青春期前的生长速率。本研究检验了这样一个假设:妊娠中期进行产前T治疗会改变胎儿胰岛素样生长因子(IGF)-胰岛素样生长因子结合蛋白(IGFBP)系统的轨迹,从而促进雌性羔羊的IUGR及随后的出生后追赶生长。分别在妊娠65、90和140天、出生时、约5个月(青春期前,追赶生长阶段)和约9.5个月(青春期后),通过放射免疫分析和Western配体印迹法测量血浆IGF-I和IGFBP。采用Northern印迹分析来测量胎儿阶段IGF系统成分的肝脏mRNA含量。在胎儿65天时,尽管体重无差异,但产前T治疗的胎儿中IGF生物活性抑制剂IGFBP-1的血浆蛋白和肝脏mRNA含量升高。产前T治疗的胎儿在胎儿90天时血浆IGF-I和IGFBP-3浓度有短暂升高。当产前T治疗的胎儿体重下降时,到140天时肝脏IGF-I mRNA和血浆IGFBP-3含量降低。产前T治疗的新生羔羊血浆IGFBP-2含量显著降低,但到4个月时,这些雌性羔羊的循环IGF-I和IGFBP-3浓度显著高于对照雌性羔羊,且生长速率更快。青春期后,产前T治疗的雌性羔羊血浆IGF-I仍保持升高。这些发现提供了证据,表明产前T过量会设定雌性绵羊IGF/IGFBP系统的发育轨迹,以在IUGR期间降低IGF生物利用度,并在青春期前追赶生长期间提高IGF生物利用度。